{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Pancreatic+Carcinoma&page=4", "query": { "condition": "Advanced Pancreatic Carcinoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 901, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Pancreatic+Carcinoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Pancreatic+Carcinoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T15:31:37.637Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05989724", "title": "A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Breast Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "SON-DP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qurgen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2023-09-19", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05989724" }, { "nct_id": "NCT04034238", "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms With Mesothelin Expression", "Epithelioid Mesothelioma", "Cholangiocarcinoma, Extrahepatic", "Adenocarcinoma, Pancreatic" ], "interventions": [ { "name": "LMB-100", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Mesothelin Expression", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-08-29", "completion_date": "2021-11-19", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04034238" }, { "nct_id": "NCT03127098", "title": "QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Thyroid Cancer", "Colon Cancer", "Ovarian Cancer", "Breast Cancer", "Lung Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NantCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 3, "start_date": "2017-06-26", "completion_date": "2017-12-07", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 1, "location_summary": "Spokane, Washington", "locations": [ { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03127098" }, { "nct_id": "NCT02394535", "title": "Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v6 and v7", "Stage IIA Pancreatic Cancer AJCC v6 and v7", "Stage IIB Pancreatic Cancer AJCC v6 and v7", "Stage III Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 25, "start_date": "2015-11-12", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2022-09-02", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 5, "location_summary": "Houston, Texas • League City, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02394535" }, { "nct_id": "NCT00033384", "title": "CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Lung Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "CI-1040", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033384" }, { "nct_id": "NCT04042480", "title": "A Study of SGN-CD228A in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Melanoma", "Pleural Mesothelioma", "HER2 Negative Breast Neoplasms", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "SGN-CD228A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2019-09-03", "completion_date": "2023-03-09", "has_results": false, "last_update_posted_date": "2023-03-23", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04042480" }, { "nct_id": "NCT00959946", "title": "Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Breast Cancer (Parts 1 and 2)", "Advanced Pancreatic Cancer (Part 1)", "Advanced Colorectal Cancer (Part 1)", "Advanced Cholangiocarcinoma (Part 1)", "Advanced Glioblastoma Multiforme (Part 1)" ], "interventions": [ { "name": "Bosutinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2009-09", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2013-02-22", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Detroit, Michigan", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00959946" }, { "nct_id": "NCT06179160", "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB161734", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "INCA33890", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2024-01-04", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179160" }, { "nct_id": "NCT02080260", "title": "A Study of Regorafenib in Advanced Pancreatic Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2014-06-06", "completion_date": "2017-06-28", "has_results": true, "last_update_posted_date": "2022-04-21", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 12, "location_summary": "Albemarle, North Carolina • Charlotte, North Carolina • Concord, North Carolina + 3 more", "locations": [ { "city": "Albemarle", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02080260" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-10-08T15:31:37.637Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" } ] }